JOINT PROGRAM EXECUTIVE OFFICE FOR CHEMICAL, BIOLOGICAL, RADIOLOGICAL AND NUCLEAR DEFENSE (JPEO-CBRND)

SUPPORT TO NATIONAL COVID-19 RESPONSE

As of 15 April 2021

Lessons Learned from COVID Response Will Inform CBDP Development of Emerging Threat Solutions Into the Future

PARTNERS

Building Success on Foundation of Partnerships with Government, Industry, Academia





























PEOPLE

Providing Critical Subject Matter Expertise Across the National Response





FULL-TIME

Technical Subject Matter Experts Embedded in Leadership Roles with Federal Response Operation



105 +

HALF-TIME OR MORE

Technical and Program Management Subject Matter Experts Supporting Assisted Acquisition Across the Whole-of-Government Response

ACQUISITION INNOVATION

ASSISTED: Supported Development and Production of Vaccines, Therapeutics and Enablers

PROCESSES


Enabling Speed and Efficiency through Innovative and New **Approaches**



OBLIGATED

|600**M**+





Pfizer SANOFI













ACCELERATED: Streamlined **Processes and Business Practices**



EFFORT

ENABLERS

 Therapeutics LINES OF Vaccines

Enablers

Diagnostics

REGULATORY Subject Matter Experts Guide Policy, Advise on Product Procurement and Development, and Streamline Processes to Inform Decisionmaking and Ensure Regulatory Compliance



PRODUCTS

Protecting and Saving Lives with the Full Spectrum of Medical Countermeasures

DIAGNOSTICS/TESTING



Surveillance Stick

Medical Mobile Lab

AstraZeneca

moderna **NOVAVAX**



Non Contact

Wearable



Assavs



Drugs



Polyclonal

Antibodies

THERAPEUTICS





Antibodies

Monoclonal

VACCINES





& Needles

Stockpile

Swabs



四







PPE



Eve Protection

Strategic National Syringes Industrial Base

Vaccines

Negatively Pressurized Conex

Expansion

PHASE Clinical Trials